ALOX5 and tuberculosis: Inhibiting 5-LOX has been linked to restricted lung pathology, lower type-I IFN production, reduced Mtb replication and greater survival rates in a TB-susceptible murine model18; thus rationalizing the prospective use as adjunctive therapy to improve TB outcome.